Aseptika Launches Innovative PUFFClicker3 Universal Inhaler Dose Counter at Med-Tech Innovation Expo

22 May 2024
Aseptika Launches Innovative PUFFClicker3 Universal Inhaler Dose Counter at Med-Tech Innovation Expo

Date: 5th June 2024, St Ives, Cambridgeshire, UK 

Today we launch the PUFFClicker3, Aseptika’s universal smart inhaler dose tracker, a world first, with an inhaler dose tracker that is compatible with both pressurised metered dose inhalers (pMDI) and dry powder inhalers (DPI). The PUFFClicker3 supports 101 SNOMED-coded inhalers for both pMDI and DPIs, making the switching to a new type of inhaler a simple process. It provides in-built graphical instructions on how to use each inhaler it supports. The innovative PUFFClicker3 smart inhaler was developed to improve inhaler adherence, for patients of all ages and for all respiratory conditions that require treatment with the use of inhalers.

Adherence to inhaler medications prescribed for chronic respiratory conditions is widely acknowledged to be poor, with an estimated half of patients not following their medication regimen as directed¹. Studies suggest that approximately 75% adherence to inhaled medication is necessary to control symptoms and reduce the risk of exacerbations². Inhaler adherence poses the primary challenge in managing respiratory conditions across all age groups, from children and young people (CYP) aged 6-18 years with poorly controlled asthma to adults with COPD, asthma and other respiratory ailments. There exists a direct correlation between medication adherence and improved outcomes, emphasising the critical importance of consistently taking inhaler medication as prescribed, particularly in preventing further asthma attacks in children and young people, COPD exacerbations, Cystic Fibrosis and other respiratory conditions.

Overcoming several technical challenges shaped the development of the PUFFClicker3. One significant obstacle was the difficulty patients encountered when pairing devices via Bluetooth to a Smartphone. To address this, we removed the necessity for smartphones to transmit data from the device to healthcare staff and parents/carers. Another factor influencing the design is the increasing number of schools banning smartphones for younger children. Consequently, the PUFFClicker3 will employ mobile IoT technology to transmit data, enabling parents and carers to receive real-time updates. This feature will alert them when their child or young person is over-using reliever inhalers, whether at school or away from home.

The development of the PUFFClicker3 received backing initially from an Innovate UK Smart Award, facilitating the elimination of smartphone dependency whilst providing patients, parents, carers and healthcare professionals with the advantage of real-time inhaler adherence monitoring data. 

As important is how the PUFFClicker3 reduces health inequities. Its interactive touch screen can show instructions in 16 languages. Removing the need for connection with a smartphone, supporting patients who are digitally hesitant.

The PUFFClicker3 universal inhaler dose counter includes:

·       Compatibility with 101 SNOMED-coded pressurised metered dose (pMDI) and dry powder inhalers (DPI), offering a Universal Inhaler Dose Counter. 
·       User-friendly design with its own touch screen for ease of operation. 
·       Incorporation of simple animated graphics and sounds, providing guidance on how to use different types of pMDI and DPI inhalers, as well as the PUFFClicker3 device itself. 
·       Inclusive design with support for 16 languages (Arabic, Bengali, Czech, English, Gujarati, Hindi, Italian, Latvian, Lithuanian, Polish, Punjabi, Romanian, Russian, Spanish, Ukrainian, and Urdu), aimed at addressing health inequities stemming from language barriers. This aligns with the NHS Core20PLUS initiative, which targets patients who can find it sometimes difficult to access healthcare. 
·       Elimination of the need for a smartphone to transmit inhaler medication adherence data to the Cloud, enabling direct communication with parents, carers and healthcare staff. Additionally, the device stores data locally, providing patients with feedback on doses taken, upcoming dosage schedules and remaining doses in the inhaler.

We are now testing PUFFClicker3 with children and young people (aged 6-18) who have poorly controlled asthma. Our aim is to gather their feedback on the usability and functionality of the device and assess how it could aid in managing their asthma, especially as they are transition to adult care. 

This Patient and Public Involvement and Engagement (PPIE) initiative is backed by funding from SBRI Healthcare Phase I, an Accelerated Access Collaborative initiative. So What? Consultancy Ltd is assisting with the PPIE and usability activities in collaboration with Health Innovation East (HIE) and with Health Innovation West Midlands (HIWM).

As part of this initiative, we are engaging with Asthma Nurses, GPs and Pharmacists to explore future pathways for introducing inhaler adherence through a straightforward 30-day implementation process, initially focusing on children and young people with poorly controlled asthma. The goal is to prompt behaviour change by providing a PUFFClicker3 device alongside inhalers, enabling data transmission for healthcare review by their healthcare professional during asthma assessments. Insights from the Cochrane Review (2022) support the efficacy of digital interventions in improving adherence to maintenance medication in asthma, highlighting those patients provided with digital technology experience better asthma control and a reduced risk of asthma attacks, leading to tangible benefits in minimising asthma-related deaths³. These findings align with outcomes observed in our clinical trial and evaluations involving children and young people with asthma and their Parents or Carers.

Reducing inhaler medication wastage contributes to carbon savings and inhaler adherence smart solutions can decrease the need for NHS emergency hospitalisations. An admission to a hospital's A&E for an asthma attack results in a significant emission of 125 Kg CO₂ per day. In contrast, a pressurised metered dose inhaler (pMDI) is associated with carbon equivalents of only 0.17 Kg CO₂. In many respects, prevention proves superior to treatment.

Professor Will Carroll (Consultant Paediatrician from University Hospitals of the North Midlands) commented:

“The truth is, admitting when things haven't gone well is challenging for both parents and young people. PUFFClicker3 removes the rose-tinted view and provides us with objective evidence of whether people are doing what they need to stay well. This is especially important for children whose asthma control isn't as good as it should be.

Inclusivity is really important in healthcare, yet we seem to have performed poorly over the last 30 to 40 years. We know that health outcomes, particularly for asthma, are worse for children whose parents' first language is not English. It's really important to ensure that any solution is accessible to everyone."

Aseptika welcomes visitors to our exhibition stand C37 at the Med-Tech Innovation Expo at the NEC on June 5-6, 2024, to experience the PUFFClicker3 universal inhaler dose tracker firsthand.
1.     NICE Clinical Guideline CG76 Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. January 2009.
2.     Williams LK, Peterson EL, Wells K, Ahmedani BK, Kumar R, Burchard EG, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. Journal of Allergy and Clinical Immunology. 2011; 128(6):1185-1191.e1182. 
3.     Chan A, De Simoni A, Wileman V, Holliday L, Chisari C, Newby CJ, Griffiths CJ, Ali S, Padakanti P, Zhu N, Ting V and Pinprachanan V. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database of Systematic Reviews, 2022, Issue 6. Art.No.:CD013030. doi: 10.1002/1451858.CD013030.pub2.

Caption: The PUFFClicker3 Universal Inhaler Dose Tracker that is compatible with 101 pressurised metered dose inhalers (pMDI) and dry powder inhalers (DPI).

Further information

Aseptika, Activ8rlives,, PUFFClicker, Asthma⁺me, Active⁺me REMOTE and BuddyWOTCH are trademarks of Aseptika Ltd.

For further details, please contact Kevin Auton on +44 (0)1480 352 821 or email

For more information about the PUFFClicker3 follow this link.
Aseptika Ltd  

Aseptika Ltd began developing Activ8rlives in 2010 and is currently developing its fourth generation of integrated systems, which can be used by consumers and their healthcare service providers using a wide range of platforms or devices to better enable effective and easy self-monitoring. Incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs). Our focus is: respiratory and cardiovascular disease, cancer, promoting physical activity and weight management. Aseptika Limited has been certified by BSI to ISO 13485:2016 under certificate number MD691414.

SBRI Healthcare

SBRI (Small Business Research Initiative) Healthcare provides funding and support to innovators to develop solutions that tackle existing unmet needs faced by the NHS. The programme aims to improve patient care, increase efficiency in the NHS, and support the UK economy. The programme provides funding and support to early-stage projects enabling testing for business feasibility and technology development, as well as to more mature products to support real world implementation studies. SBRI Healthcare is funded by the Accelerated Access Collaborative and delivered in partnership with the Health Innovation Network. 

So What? Consultancy Ltd

SoWhat? Consultancy is a team of experienced senior executives specialising in life sciences, health, and social care. They hold roles within the NHS, offering insights into its needs and priorities. The team has expertise in pharmaceuticals, digital and medical technologies, and a range of healthcare conditions. Services include healthcare insights, market access, health economic evaluations, data synthesis, and stakeholder validations. By asking “Where’s the ‘So what?’” we make sure that our clients are provided with deep insight and synthesis, accurate and credible recommendations and support to shape and implement the solutions.

Health Innovation East

Health Innovation East (the new name for Eastern AHSN) believes that great ideas only make a difference for our health when they are put into practice. A team of expert advisors, programme leaders and specialist technologists they are passionate about helping the best innovations in health and care reach the people, places and problems where they bring most benefit. Health Innovation East is the regional innovation arm of the NHS, this means that as well as working on technology enabled change programmes alongside NHS clinicians and managers, they also support wider the health and life sciences industry to position products for use across the healthcare system. As part a national Health Innovation Network, Health Innovation East is ideally positioned to help scale up innovations - working collaboratively the network has for example, supported the introduction of new ways of managing cardiovascular disease, enabled children and young people to benefit from better access to therapies for eating disorders, and leveraged well over £1 billion of investment into the UK’s health and life sciences industries.

Health Innovation West Midlands

Health Innovation West Midlands (HIWM) leads and catalyses collaboration between academia, industry, health and care providers, commissioners and citizens to support continuous improvement of our region’s health and wealth. As part of the national Health Innovation Network, funded by NHS England, we seek out, test and accelerate the adoption and spread of innovative ideas and technologies with the potential to transform health and social care in the West Midlands and beyond.

We work to transform health and social care across the West Midlands by supporting the development of innovation and giving patients access to the most effective medical discoveries. By enabling the healthcare system to take advantage of innovations that can help to save time, money and lives, the HIWM is working to bring the West Midlands the future of health and social care, today.

Powered by Amasty Magento 2 Blog Extension